A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver
This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.
Liver Cancer
DRUG: Pemetrexed
Antitumor activity as measured by Response Evaluation Criteria in Solid Tumors
Toxicity measured by CTCAE grading|Duration of response: First complete or partial response until progressive disease (PD) or death of any cause|Duration of stable disease: Enrollment to PD or death of any cause|Time to treatment failure: Enroll. to PD, death of any cause, early discontinuation of treatment for any reason other than adequate response or start of new therapy|Progression-free survival: Enroll. to PD or death of any cause|Overall survival: Enroll. to death of any cause
This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.